{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T23:57:48Z","timestamp":1776211068898,"version":"3.50.1"},"reference-count":13,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T00:00:00Z","timestamp":1493337600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2017,11]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Blinatumomab is a bispecific T\u2010cell engaging \u03b1CD19 antibody used in refractory or relapsed B\u2010cell precursor acute lymphoblastic leukemia (ALL). Recently, lineage switch to a myeloid phenotype has been described following CD19 targeting treatment in three pediatric patients with mixed lineage leukemia (MLL) rearranged ALL. We report the case of a female who received blinatumomab for a first relapse of ALL without MLL alterations. She suffered from a second relapse early after hematopoietic stem cell transplantation and was treated with blinatumomab again. During this treatment, the leukemia lost CD19 expression as well as nearly all other B\u2010cell markers, while still harboring the initial minimal residual disease marker, and switched to a myeloid phenotype.<\/jats:p>","DOI":"10.1002\/pbc.26594","type":"journal-article","created":{"date-parts":[[2017,4,28]],"date-time":"2017-04-28T19:07:00Z","timestamp":1493406420000},"source":"Crossref","is-referenced-by-count":58,"title":["Lineage switch under blinatumomab treatment of relapsed common acute lymphoblastic leukemia without MLL rearrangement"],"prefix":"10.1002","volume":"64","author":[{"given":"Annabelle","family":"Zoghbi","sequence":"first","affiliation":[{"name":"Clinic of Pediatric Hematology and Oncology University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Udo","family":"zur Stadt","sequence":"additional","affiliation":[{"name":"Center of Diagnostics University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beate","family":"Winkler","sequence":"additional","affiliation":[{"name":"Clinic of Pediatric Hematology and Oncology University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ingo","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Clinic of Pediatric Hematology and Oncology University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriele","family":"Escherich","sequence":"additional","affiliation":[{"name":"Clinic of Pediatric Hematology and Oncology University Medical Center Hamburg\u2010Eppendorf  Hamburg Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2017,4,28]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V95.6.2098"},{"issue":"70","key":"e_1_2_6_3_1","article-title":"A phase 1\/2 study of blinatumomab in pediatric patients with relapsed\/refractory B\u2010cell precursor acute lymphoblastic leukemia","volume":"122","author":"Stackelberg A","year":"2013","journal-title":"Blood"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-07-441030"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.56.3247"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-08-665547"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25953"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.23266"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404586"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.239"},{"issue":"21","key":"e_1_2_6_11_1","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood.V124.21.2292.2292","article-title":"Phase 1\/2 study in pediatric patients with relapsed\/refractory B\u2010cell precursor acute lymphoblastic leukemia (BCP\u2010ALL) receiving blinatumomab treatment","volume":"124","author":"Stackelberg A","year":"2014","journal-title":"Blood"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404718"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12320"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-05-718395"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpbc.26594","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.26594","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T03:37:55Z","timestamp":1696477075000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.26594"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4,28]]},"references-count":13,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["10.1002\/pbc.26594"],"URL":"https:\/\/doi.org\/10.1002\/pbc.26594","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"value":"1545-5009","type":"print"},{"value":"1545-5017","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,4,28]]},"article-number":"e26594"}}